GlobeNewswire Inc.··Hutchmed (China) LimitedHUTCHMED Launches Global Trial for Dual-Action Tumor Therapy HMPL-A580
HUTCHMED initiates Phase I/IIa trial of HMPL-A580, a novel antibody-targeted therapy combining PI3K/PIKK inhibitor with anti-EGFR antibody for solid tumors across China and US.
HCMclinical developmentsolid tumors